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Abstract: Human immunodeficiency virus type-1 (HIV-1) and human
T lymphotropic virus type-1 (HTLV-1) infections have complex effects
on adaptive immunity, with specific tropism for, but contrasting effects
on, CD4 T lymphocytes: depletion with HIV-1, proliferation with
HTLV-1. Impaired T lymphocyte function occurs early in HIV-1
infection but opportunistic infections (OIs) rarely occur in the absence
of CD4 lymphopenia. In the unusual case where a HIV-1 infected
individual with a high CD4 count presents with recurrent OIs, a clinician
is faced with the possibility of a second underlying comorbidity.
We present a case of pseudo-adult T cell leukemia/lymphoma
(ATLL) in HIV-1/HTLV-1 coinfection where the individual fulfilled
Shimoyama criteria for chronic ATLL and had pulmonaryMycobacter-
ium kansasii, despite a high CD4 lymphocyte count. However, there was
no evidence of clonal T-cell proliferation by T-cell receptor gene
rearrangement studies nor of monoclonal HTLV-1 integration by
high-throughput sequencing. Mutually beneficial interplay between
HIV-1 and HTLV-1, maintaining high level HIV-1 and HTLV-1
viremia and proliferation of poorly functional CD4 cells despite chroni-Kagdi, MB, FRCP ake, MSc,
k, MB, MD, and G.P. Taylor, MB, DSc
anemia. Subsequent initiation of combined antiretroviral therapy led
to paradoxical resolution of CD4 T lymphocytosis as well as HIV-1 viral
suppression and decreased HTLV-1 proviral load. This is proposed to be
the result of attenuation of immune activation post-HIV virological
control.
This case illustrates the importance of screening for HTLV-1 in
HIV-1 patients with appropriate clinical presentation and epidemiolo-
gical risk factors and explores mechanisms for the complex interactions
on HIV-1/HTLV-1 adaptive immunity.
(Medicine 94(50):e2275)
Abbreviations: AIDS = acquired immunodeficiency syndrome,
ATLL = adult T cell leukemia/lymphoma, BAL = bronchoalveolar
lavage, cART = combination antiretroviral therapy, CSF =
cerebrospinal fluid, DNA = deoxyribonucleic acid, HAM =
HTLV-1 associated myelopathy, Hb = hemoglobin, HIV-1 =
human immunodeficiency virus type-1, HPLC = high
performance liquid chromatography, HTLV-1 = human
T lymphotropic virus type-1, NR = normal range, OI =
opportunistic infection, PBMCs = peripheral blood mononuclear
cells, PVL = proviral load, STLV = simian T-lymphotropic virus,
TCR = T cell receptor, UIS = unique integration site, VL = viral
load.
INTRODUCTION
H uman immunodeficiency virus type-1 (HIV-1) is wellknown to cause opportunistic infection (OI) and this is
typically accompanied by declining levels of CD4 T-lympho-
cytes leading to impaired cell-mediated immunity. In the unu-
sual case where a HIV-1 infected individual with a high CD4
cell count presents with recurrent infections, a clinician is faced
with the possibility of a second underlying comorbidity. Coin-
fection with a second retrovirus, human T lymphotropic virus
type-1 (HTLV-1), should also be considered, particularly in
individuals of specific ethnic or geographic origins with a
prevalence of greater than 1% in the general population.
HIV-1 and HTLV-1 infections have complex effects on adap-
tive immunity, with specific tropism for, but contrasting effects
on CD4þ T-cells.
An estimated 10 to 20 million people worldwide are
infected with HTLV-1 with prevalence exceeding 1% in
southern Japan, central Africa, and the Caribbean.1 HTLV-1
infection is associated with asymptomatic carriage in more than
90% of infections. HTLV-1 associated myelopathy (HAM)f carriers and the life-time risk of adult
oma (ATLL) is 1% to 5%.2 HTLV-1 is
range of inflammatory diseases: HAM,
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41.8 % CSF white cells (paired PBMC PVL 28.2 %). After
nine months on cART, HIV VL was undetectable in plasma,
with decreases in HTLV-1 PVL to 10.7% PBMCs and CD25uveitis, pneumonitis, lymphocytic arthritis, and bronchiectasis.
HTLV-1 infection is also associated with a range of infections
implying selective immune impairment, most notably dissemi-
nated strongyloides infection, Norwegian scabies, infective
dermatitis, bladder, and kidney infections.1,2
Rhew et al’s3 review of the literature showed that being a
carrier for HTLV-1 was a risk factor for OI, particularly
following the development of ATLL. There have been con-
flicting reports of the prevalence of HTLV-1 and Mycobacter-
ium tuberculosis (MTB) coinfection in case–control studies
carried out in geographical areas with high HTLV-1 preva-
lence.4–7
A patient with HIV-1/HTLV-1 coinfection presenting with
an acquired immunodeficiency syndrome (AIDS) defining
diagnosis of Mycobacterium kansasii and pseudo-adult T-cell
leukemia/lymphoma (ATLL) is presented. The mechanism of
potentiated immune activation driving proliferation is postu-
lated. Informed consent was obtained from the patient before all
investigations and before publication of this case report.
CASE
The patient, a 47-year-old West Indian man was diagnosed
with HIV-1 infection in the United Kingdom in 2002. He was
heterosexual, had no history of injecting drug use and had a
20 pack year smoking history. He originally presented with
recurrent cutaneous fungal infections, bacterial tonsillitis, var-
icella zoster infection, and oral candida. At diagnosis, his CD4
lymphocyte count was 757 cells/mm3 (normal range [NR] 300–
1400) and HIV-1 viral load (VL) was 26,905 copies/ml.
He remained clinically stable without antiretroviral
therapy until 2010 when he presented with symptomatic ane-
mia, night sweats, and a productive cough unresponsive to
courses of antibiotics in the community. He also complained
of erectile dysfunction and obstructive urinary tract symptoms.
He had notable xeroderma, oral candida, obstructive airway
chest wall movements, a peak expiratory flow rate of 300L/
minute (predicted 580L/minute), coarse widespread crepita-
tions on auscultation and palpable hepatosplenomegaly. He had
normal tone and power, brisk lower limb reflexes with down-
going plantar responses, conserved sensation, and normal
anal tone.
Salient laboratory findings were: erythrocyte sedimen-
tation rate of 126mm/hour (NR 0–10mm/hour), hemoglobin
(Hb) 7 g/dl (NR 12.5–17.0), mean cell volume 76.8 fl (NR
83.0–101.0), ferritin 410mg/L (NR 20–300), high performance
liquid chromatography (HPLC) showed HbC 67.8%; HbA2
4.6% (NR 2.0–3.3%); HbF 5.6% (NR 0–1%). Blood film
showed anisopoikilocytosis, mature lymphocytosis with 14%
atypical lymphocytes and no flower cells. Serum B12: 360 ng/L
(NR 160–800), red cell folate: 145.6 ng/ml (NR 126–480),
iron: 23mmol/L (NR 9–29), Total iron binding capacity:
31mmol/L (NR 49–78), transferrin saturation: 74 (NR 20–
45%), pretransfusion reticulocyte count was 48.9 109 (NR
28.1–86.1 109), reticulocyte %: 1.6 (0.52–1.84%). A vascu-
litic screen was negative for anticyclic citrullinated peptide,
antineutrophil cytoplasmic antibody, antinuclear antibody, and
antiglomerular basement antibody. Serology revealed no evi-
dence of previous or current hepatitis B or C virus infection.
There was no evidence of hematological malignancy, Epstein–
Barr virus, parvovirus or human herpes virus-8 infection on
N et albone marrow examination. Upper and lower gastrointestinal
endoscopy revealed only chronic gastritis. Serum albumin
was 24 g/L (NR 22–47) and liver transaminases and bone
2 | www.md-journal.combiochemical profile were unremarkable. Urinalysis revealed
microscopic hematuria and proteinuria with a urine protein:-
creatinine ratio of 146 (normal range <20). His estimated
glomerular filtration rate was 79ml/minute/1.73m2
(NR>59ml/minute/1.73m2) and computerized tomography
of kidneys, ureters and bladder, flexible cystoscopy, renal,
and prostate ultrasound were unremarkable. Computerized
tomography of the thorax revealed bilateral upper lobe bronch-
iectasis along with several ill-defined nodules, some with
cavitation, and foci of consolidation in both the upper lobes,
significant right middle lobe consolidation and associated
volume loss (Figure 1). Bronchoalveolar lavage (BAL) wash-
ings revealed an acute inflammatory response with no malig-
nant cells. M. kansasii grew from BAL and sputum culture.
HIV-1 VL at this time was 4.62 106 copies/ml, absolute
lymphocyte count 8000 cells/mm3 (NR 1100–3600) and
CD4þ count 2239 cells/mm3.
Despite sputum culture conversion within 6 months of
antimycobacterial therapy (rifampicin, isoniazid, ethambutol),
he remained symptomatic with weight loss, productive cough,
and refractory anemia requiring multiple transfusions. HIV-1
VL was now 7.44 106 copies/ml, CD4þ count 2477 cells/
mm3. At this point HTLV-1 infection was considered and
anti-HTLV-antibodies were detected with Western blot confir-
mation. HTLV-1 proviral load (PVL) was 42.9 deoxyribonu-
cleic acid (DNA) copies/100 peripheral blood mononuclear
cells (PBMCs).8 Ninety-two percent of CD4þ lymphocytes
expressed CD25 (NR 15.7–34.9) with no evidence of clonal
T cell receptor (TCR) gene rearrangement.
Combination antiretroviral therapy (cART) was com-
menced in August 2011 with emtricitabine, etravirine, and
darunavir/ritonavir (a tenofovir sparing regimen was selected
in light of his renal function). Within 3 months, he showed
clinical and radiological improvement. The CD4þ count
decreased to 1495/mm3 HTLV-1 PVL to 20.4% and HIV VL
to 5098 copies/ml. Cerebrospinal fluid (CSF) obtained 4 months
postinitiation of cART revealed 538 copies/ml CSF (paired
plasma HIV VL 932 copies/ml) and CSF HTLV-1 PVL of
Medicine  Volume 94, Number 50, December 2015FIGURE 1. CT thorax at the time of diagnosis of M. kansasii
showing consolidation and bronchiectasis in upper lobes bilater-
ally.
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expression on CD4þ cells to 87%. Table 1 summarizes total
lymphocyte, CD4 lymphocyte count, HIV-1 and HTLV-1 VL
before and in response to cART.
At HTLV-1 diagnosis, HTLV-1 unique integration site
(UIS) analysis by Illumina high-throughput sequencing9
revealed a polyclonal distribution in which the largest clone
contributed 1.77% of the total HTLV-1 PVL. One year later,
HTLV-1 PVL 19%, the polyclonal distribution was similar and
the same clone remained largest, contributing 0.96% of the total
HTLV-1 PVL (Figure 2).
At HTLV-1 diagnosis, the majority of CD4þ T cells, as
determined by flow cytometry, were effector memory cells
(TEM, CD45RA
CCR7–94.9%). The CD4 TEM cells had
CCR4þCD25þCD127lowFOXP3 immunophenotype. One
year later, there was reduction in both absolute and relative
Medicine  Volume 94, Number 50, December 2015frequency of CD4 T cells but no change in immunopheno-EM
type.
He remains well 4 years later.
DISCUSSION
This case caused diagnostic uncertainty since the absolute
lymphocyte count, HTLV-1 serology and % atypical lympho-
cytes fulfilled Shimoyama criteria10 for the diagnosis of chronic
ATLL. However, there was no evidence of clonal T-cell
proliferation by TCR gene rearrangement studies nor of mono-
clonal HTLV-1 integration by high-throughput sequencing.
HTLV-1 infection results in increased T lymphocyte pro-
liferation, which is usually balanced by a higher rate of infected
cell death due to immune surveillance.2 Total lymphocyte, CD4
and CD8 T lymphocyte subsets are usually within the normal
range in HTLV-1 mono-infection. Unlike HIV-1 infection in
which viremia is maintained by infectious spread, HTLV-1
PVL, in chronic infection is thought to be substantially main-
tained by proliferation of infected cells and HTLV-1 integration
site analysis reveals multiple clonal expansions of CD4lymphocytes.9 The very high HIV-1 viremia, despite the
hronicity of infection, may reflect the abnormally high CD4
ell count due to HTLV-1 infection, similar to that seen in
infectious spread.13–16 The normalization of the CD4þ cell
count, with a paradoxical decrease in CD4þ count during
HIV-specific cART, suggested proliferation of HTLV-1-
ABLE 1. Total Lymphocyte, CD4 Lymphocyte Count, Human Immunodeficiency Virus-1 and Human T-Lymphotrophic Virus
ype-1 Viral Load Before and in Response to Combination Antiretroviral Therapy
ime Point June 2003 November 2010 August 2011 November 2011 April 2012
tage of clinical
management
Time of
diagnosis of
HIV-1
Pre-commencement
of M. kansasii
treatment
Month 6 of M. kansasii
treatment/pre-commencement
of cART
3 months after
commencement
of cART
9 months after
commencement
of cART
otal lymphocyte
count (cells/mm3)
(NR 1100–3600)
6197 8000 5900 4600 2600
D4 lymphocyte
count (cells/mm3)
(NR 300–1400)
757 2239 2477 1495 939
IV-1 viral load
(copies/ml)
26,905 4.62 106 7.44 106 5098 <40
TLV-1 proviral
load (DNA copies/
100 PBMC)
Unknown Unknown 42.9 20.4 10.7T
c
c
T
T
T
S
T
C
H
HcART¼ combination antiretroviral therapy; DNA¼ deoxyribonucleic a
lymphotropic virus type-1; PBMC¼ peripheral blood mononuclear cells.
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predominantly due to an increased frequency of activated
CD4þCCR4þ TEM cells. A high proportion of HTLV-1 infected
cells express CCR4. It has been suggested that active HIV
infection increases CCR4þ T-cells via secretion of the CCR4
ligands TARC and MDC by activated monocyte/macro-
phages.11 This would result in the proliferation of HTLV-1-
infected CCR4þ T cells. We postulate that the coinfection with
the 2 viruses led to overproduction of poorly functional lympho-
cytes whilst providing an environment for high levels of HIV
virion production. It is possible that CD4þT-lymphocytes were
coinfected with the 2 viruses, but we have not been able to
demonstrate this.
If, despite the high CD4 cell count, HIV-1 was contributing
to high CD4 lymphocyte turnover, treatment of HIV-1 with
cART might be expected to further increase the CD4 cell count,
unmasking the true degree of HTLV-1 related CD4 T lympho-
cyte proliferation. Data from Beilke et al12 suggest that where
individuals with HIV/HTLV-1 coinfection have high HTLV-1
VL, cART has limited efficacy in controlling HTLV-1 viremia.
However, in this subject cART, which was HIV-1 specific, was
associated with normalization of CD4þ counts and a significant
decrease in the proportion of PBMCs infected with HTLV-1.
Whilst zidovudine with lamivudine has not impacted on HTLV-
1 VL in patients with HAM,13 zidovudine in combination
with interferon-a2a has improved the outcome in ATLL.14
Raltegravir has been shown to prevent HTLV-1 infection in
vitro.15 In baboons infected with simian (S) TLV-1, treatment
with sodium valproate, combined with zidovudine, resulted in
significant, sustained reduction in STLV-1 VL.16 Raltegravir
may be a suitable alternative, since the role of ART combined
with histone deacetylase inhibition is to prevent an initial
increase in HTLV-1 viral replication associated with increased
HTLV-1 transcription. The anti-HTLV-1 efficacy of zidovu-
dine, raltegravir, and histone deacetylase inhibitors requires
further clinical evaluation and may only impact on continuing
Immune Reconstitution in HIV/HTLV Coinfectioncid; HIV-1¼ human immunodeficiency virus-1; HTLV-1¼ human T
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FIGURE 2. Relative abundance of integration sites. Each pie chart
depicts the clonal abundance of unique integration sites using
linker-mediated polymerase chain reaction (PCR) followed by
high throughput sequencing. Each slice of the pie chart represents
the relative abundance of an individual clone within that sample.
Precombined antiretroviral therapy (cART), the relative abun-
dance of the largest clone (blue) represents 1.77% of the PVL
(76.3/10,000 peripheral blood mononuclear cells (PBMC)) and
following 1 year of cART reduces to 0.96% of PVL (18.3/10,000
N et alinfected CD4 T-cells driven by HIV-related immune activation;
this interpretation was supported by the observation of poly-
clonal HTLV-1 integration at both time points.
In conclusion, we present a case of pseudo-ATLL in a
HIV-1 infected individual whose high CD4 counts were decep-
tive as he was significantly immunosuppressed. His high CD4
count and ethnic origin prompted screening for HTLV-1 coin-
fection. Paradoxically, there was a significant improvement of
CD4 lymphocytosis and HTLV-1 VL post commencement of
HIV-1 specific cART. We postulate that mutually beneficial
interplay between HIV-1 and HTLV-1 maintained high loads of
each virus, and proliferation of poorly functional CD4þ cells
despite chronic infection. We suggest that the likely mechanism
was immune activation of T-cells, which was attenuated by
HIV-1 virological control with cART.
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